MAP2K1 and cancer: RAF/MEK/ERK signaling pathway has been confirmed to be promising therapeutic targets for cancer, among which RAF1 plays a key role in activating the phosphorylation of downstream MEK1/MEK2 and ERK1/ERK2 and promoting cancer progression [20].